PAVmed Appoints Joseph Virgilio as Chief Business Officer to Boost Medical Device Innovation
- PAVmed appoints Joseph Virgilio as Chief Business Officer to enhance medical device development and commercialization efforts.
- Virgilio brings over 25 years of medical device experience, expected to drive PAVmed's growth and innovation.
- PAVmed aims to expand its medical device pipeline, focusing on innovation and improving patient outcomes in healthcare.
PAVmed Appoints New Chief Business Officer to Drive Medical Device Innovation
PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, takes a significant step forward by appointing Joseph Virgilio as Senior Vice President and Chief Business Officer for Medical Devices. This strategic move is anticipated to enhance PAVmed’s focus on developing and commercializing its medical device portfolio. The appointment comes at a pivotal time as the company works to relaunch its initiatives following recent improvements in its capital structure. Dr. Lishan Aklog, PAVmed's Chairman and CEO, emphasizes that Virgilio’s extensive experience and established leadership in the medical device industry are expected to propel the company’s growth and innovation.
Virgilio arrives with over 25 years of experience in the medical device sector, having held key leadership roles at companies such as Morphic Medical and Amann Girrbach North America LP. His previous successes include steering regulatory initiatives and securing significant funding to foster business growth. With a background that spans critical positions at Boston Scientific and Medtronic, Virgilio possesses a wealth of knowledge in enhancing commercial strategies that are crucial for PAVmed's expansion plans. His track record positions him as an ideal candidate to lead the upcoming developments in PAVmed's medical device operations, which play a vital role in the company's broader strategy.
As PAVmed aims to increase its footprint in the medical technology landscape, the relaunch of its medical device initiatives under Virgilio's guidance reflects the company’s commitment to innovation. By adopting a shared services model across its subsidiaries, PAVmed is focused on streamlining operations and tapping into new commercial opportunities. This strategic alignment seeks not only to bolster product development and market entry but also to enhance long-term shareholder value in a competitive and rapidly evolving industry.
In addition to the new leadership appointment, PAVmed continues to emphasize its commitment to expanding its pipeline in medical devices, diagnostics, and digital health. As the healthcare landscape evolves, the company aims to provide innovative medical solutions that address emerging market needs and improve patient outcomes. This robust approach aims to secure PAVmed's position within the medical technology sector, paving the way for future successes and advancements.